Healio (9/22, Gramigna) reports research indicates that “antipsychotic treatment did not increase risk for mortality among adults with serious mental illness diagnosed with COVID-19 infection.”
Psychiatric News (9/22) reports that included in the analysis were 464 adult patients “who were diagnosed with COVID-19 infection between March 3, 2020, and February 17, 2021, and who had a preexisting diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.” Of this group, 196 were “treated with antipsychotic medication.” The findings were published online Sept. 22 in a research letter in JAMA Psychiatry.
Related Links:
— “Antipsychotics do not increase COVID-19 mortality risk “Joe Gramigna, Healio, September 22, 2021